Good morning :)
Place Order
Add to Watchlist

Laurus Labs Ltd

LAURUSLABS

Laurus Labs Ltd

LAURUSLABS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹26,170 cr, stock is ranked 298
Moderate RiskStock is 2.22x as volatile as Nifty
485.403.18% (-15.95)
485.403.18% (-15.95)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹26,170 cr, stock is ranked 298
Moderate RiskStock is 2.22x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹26,170 cr, stock is ranked 298
Moderate RiskStock is 2.22x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
176.586.360.16%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.236.560.48%

Forecast & Ratings

Detailed Forecast 
58%
Analysts have suggested that investors can buy this stock

from 12 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 17.03%, vs industry avg of 9.04%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 1.05% to 1.34%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 11.35%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,781.941,937.032,085.362,308.072,837.644,837.174,950.876,046.555,067.175,079.20
Raw Materialssubtract1,033.241,031.671,088.411,267.631,629.552,455.202,414.942,752.282,533.304,271.97
Power & Fuel Costsubtract57.9666.2794.21109.37136.77157.75204.47324.10338.15
Employee Costsubtract175.46204.73238.14276.33320.77397.04469.55557.43614.85
Selling & Administrative Expensessubtract67.9792.2596.07140.99189.38239.88276.15291.01335.07
Operating & Other expensessubtract80.75102.10126.03141.61-9.3012.96148.03523.54441.96
Depreciation/Amortizationsubtract86.41105.98125.45164.19187.27205.07251.49324.08384.58400.09
Interest & Other Itemssubtract111.1199.9079.6488.1989.5968.16102.39165.17182.90192.90
Taxes & Other Itemssubtract35.3043.8669.8125.9938.34317.53256.33318.8375.8166.03
EPS0.861.813.171.774.7918.3615.4114.692.982.75
DPS0.100.300.300.300.502.002.002.000.800.80
Payout ratio0.120.170.090.170.100.110.130.140.270.29

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Apr 28PDF
Jan 28PDF
Jan 27PDF
+2 more
FY 2023

Annual report

PDF

Investor Presentation

Apr 27PDF
Jan 30PDF
Oct 21PDF
Jul 27PDF
FY 2024

Annual report

PDF

Investor Presentation

Jul 27PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Laurus Labs Ltd163.016.360.16%
Sun Pharmaceutical Industries Ltd46.006.560.74%
Cipla Ltd32.364.980.79%
Torrent Pharmaceuticals Ltd68.6516.580.83%

Price Comparison

Compare LAURUSLABS with any stock or ETF
Compare LAURUSLABS with any stock or ETF
LAURUSLABS
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.12%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding27.18%9.18%4.38%25.67%33.59%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun22.42%22.52%24.03%25.39%25.97%25.67%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 2.50%

Top 5 Mutual Funds holding Laurus Labs Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
SBI Large & Midcap Fund - Growth - Direct Plan

Growth
0.9467%0.93%0.93%38/87 (+28)
Mirae Asset Midcap Fund - Growth - Direct Plan

Growth
0.6807%1.05%-0.38%27/87 (-10)
Kotak Equity Arbitrage Fund - Growth - Direct Plan

Growth
0.6109%0.31%0.01%152/181 (-2)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

LAURUSLABS has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.16%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.58 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateMay 8, 2024

Interim 2
Interim 2 | Div/Share: ₹0.40

Dividend/Share

0.40

Ex DateEx Date

May 8, 2024

Cash Dividend

Ex DateEx DateNov 2, 2023

Interim
Interim | Div/Share: ₹0.40

Dividend/Share

0.40

Ex DateEx Date

Nov 2, 2023

Cash Dividend

Ex DateEx DateMay 10, 2023

Interim 2
Interim 2 | Div/Share: ₹1.20

Dividend/Share

1.20

Ex DateEx Date

May 10, 2023

Cash Dividend

Ex DateEx DateNov 3, 2022

Interim
Interim | Div/Share: ₹0.80

Dividend/Share

0.80

Ex DateEx Date

Nov 3, 2022

Cash Dividend

Ex DateEx DateMay 10, 2022

Interim 2
Interim 2 | Div/Share: ₹1.20

Dividend/Share

1.20

Ex DateEx Date

May 10, 2022

News & Opinions
Corporate
Laurus Labs inaugurates new R&D center at IKP Knowledge Park

Laurus Labs announced the inauguration of its state of the art new R&D center at IKP Knowledge Park, Plot No DS15, Kolthur Shamirpet Medchal Telangana. Key highlights: - Total investment incurred for setting up the new R&D Rs 250 crore - 2,00,000 Square foot facility equipped with modern laboratories and infrastructure - R&D Center to support the CDMO business of Laurus Labs - Will provide job opportunities to over 800 peoplePowered by Capital Market - Live

2 days agoCapital Market - Live
Spotlight
Laurus Labs Hyderabad unit clears USFDA inspection

The pharmaceutical company said that its API manufacturing facility located at Hyderabad has completed the United States Food and Drug Administration (USFDA) inspection without any 483 observation. The USFDA conducted the inspection from 9 September 2024 to 13 September 2024. Laurus Labs' API manufacturing facility, located at DS-1, IKP Knowledge Park, Genome Valley, Shameerpet, Telangana is instrumental in developing active pharmaceutical ingredients, bolstering the company's ability to deliver high-quality, innovative pharmaceutical solutions to its global customers. Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral, oncology drugs, cardiovascular, gastro and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations, provide contract research and manufacturing services (CRAMS) to global pharma companies. The company's consolidated net profit dropped 49.7% to Rs 12.51 crore in Q1 FY24 as against Rs 24.85 crore reported in Q1 FY24. Net sales was at Rs 1,194.91 crore in Q1 FY25, up 1.1% from Rs 1,181.79 crore recorded in the same period a year ago. Shares of Laurus Labs shed 0.25% to settle at Rs 505.70 on Friday, 13 September 2024.Powered by Capital Market - Live

4 days agoCapital Market - Live
Spotlight
Laurus Labs Ltd soars 4.39%

Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 496.5, up 4.39% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Laurus Labs Ltd has risen around 17.43% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has risen around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 77.3 lakh shares today, compared to the daily average of 21.43 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 497.85, up 4.08% on the day. Laurus Labs Ltd is up 21.9% in last one year as compared to a 28.41% spurt in NIFTY and a 52.01% spurt in the Nifty Pharma index.The PE of the stock is 107.07 based on TTM earnings ending June 24.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Laurus Labs Ltd spurts 1.39%, up for five straight sessions

Laurus Labs Ltd rose for a fifth straight session today. The stock is quoting at Rs 443.5, up 1.39% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.11% on the day, quoting at 24726.7. The Sensex is at 80745.92, down 0.07%. Laurus Labs Ltd has added around 0.45% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 9.31% in last one month and is currently quoting at 22374.25, up 0.85% on the day. The volume in the stock stood at 6.56 lakh shares today, compared to the daily average of 29.12 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 444.05, up 1.25% on the day. Laurus Labs Ltd is up 13.35% in last one year as compared to a 27.48% gain in NIFTY and a 47.45% gain in the Nifty Pharma index.The PE of the stock is 98.42 based on TTM earnings ending June 24.Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Spotlight
Laurus Labs Ltd rises for third consecutive session

Laurus Labs Ltd gained for a third straight session today. The stock is quoting at Rs 435.5, up 1.4% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 24574.45. The Sensex is at 80465.57, up 0.04%. Laurus Labs Ltd has slipped around 1.36% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has slipped around 7.84% in last one month and is currently quoting at 22106.5, up 0.69% on the day. The volume in the stock stood at 6.04 lakh shares today, compared to the daily average of 30.63 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 435.6, up 0.93% on the day. Laurus Labs Ltd is up 12.03% in last one year as compared to a 26.71% spurt in NIFTY and a 45.17% spurt in the Nifty Pharma index.The PE of the stock is 96.89 based on TTM earnings ending June 24.Powered by Capital Market - Live

1 month agoCapital Market - Live

Laurus Labs Ltd soars 2.21%, Gains for third straight session

1 month agoBusiness Standard

Hot stocks: Brokerage view on Ramco Cements, Tech Mahindra, Laurus Labs, Syngene and Cyient

1 month agoEconomic Times

Laurus Labs Q1 net slumps to ₹13 crore on lower revenue

1 month agoThe Hindu

Board of Laurus Labs appoints director

1 month agoBusiness Standard
Corporate
Board of Laurus Labs appoints director

The Board of Laurus Labs at its meeting held on Ramesh Subrahmanian (DIN: 02933019) as an Additional Director in the capacity of Independent Director of the Company with effect from 25 July 2024 for a tenure of 5 years, , subject to approval of the shareholders.Powered by Capital Market - Live

1 month agoCapital Market - Live